(5-甲基-1-苯基-1H-吡唑-4-基)甲醇 | 153863-35-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: (5-甲基-1-苯基-1H-吡唑-4-基)甲醇
• 中文别名: 5-甲基-1-苯基-1H-吡唑-4-基)甲醇
• 英文名称: (5-methyl-1-phenyl-1H-pyrazol-4-yl)methanol
• 英文别名: [(1-phenyl)-5-methyl-1H-pyrazole-4-yl]-methanol；(5-Methyl-1-phenylpyrazol-4-yl)methanol
• CAS: 153863-35-5
• 化学式: C₁₁H₁₂N₂O
• 分子量: 188.229
• InChiKey: JTNWKZVHKLAHTN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  38
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2933199090
• WGK Germany：
  3

SDS

Name:	(5-Methyl-1-phenyl-1h-pyrazol-4-yl)methanol 97% Material Safety Data Sheet
Synonym:
CAS:	153863-35-5

Section 1 - Chemical Product MSDS Name:(5-Methyl-1-phenyl-1h-pyrazol-4-yl)methanol 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
153863-35-5	(5-Methyl-1-phenyl-1H-pyrazol-4-yl)met	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 153863-35-5: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 88 - 89 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C11H12N2O
Molecular Weight: 188.23

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 153863-35-5 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
(5-Methyl-1-phenyl-1H-pyrazol-4-yl)methanol - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 153863-35-5: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 153863-35-5 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 153863-35-5 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (5-甲基-1-苯基-1H-吡唑-4-基)甲醇 在 氢溴酸 、 溶剂黄146 作用下， 以 二甲基亚砜 为溶剂， 反应 15.17h， 生成 1H-吡唑-3-甲腈,4,5-二甲基-1-苯基-
  参考文献：
  名称：

  5-取代的1-芳基-1 H-吡唑-4-乙腈，4-甲基-1-苯基-1 H-吡唑-3-腈和具有药理活性的1-芳基-1 H-吡唑-4-乙酸的合成

  摘要：

  氢化铝锂还原5-取代或未取代的乙基或甲基1-芳基-1 H-吡唑-4-羧酸酯通常以优异的收率得到5-取代或未取代的1-芳基-1 H-吡唑-4-甲醇在乙酸溶液中用氢溴酸得到相应的1-芳基-4-（溴甲基）-1 H-吡唑。这些粗中间体仅在未取代的化合物为5的情况下与氰化钾在二甲亚砜溶液中形成的芳基1-芳基-1 H-吡唑-4-乙腈，否则为5取代的1-芳基-1 H-吡唑-4的混合物通常获得-乙腈和4-甲基-1-苯基-1 H-吡唑-3-腈。乙腈通过碱水解，IIIa，b，i，1以优异的产率得到相应的1-芳基-1 H-吡唑-4-乙酸Va，b，i，l。化合物Vb，i，l在扭体试验中显示出明显的镇痛特性，与低急性毒性有关；此外，化合物VI在角叉菜胶诱导的水肿测定中显示出统计学上显着的抗炎活性。

  DOI：

  10.1002/jhet.5570300427
• 作为产物：
  描述：

  5-甲基-1-苯基-1H-吡唑-4-羧酸甲酯 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 生成 (5-甲基-1-苯基-1H-吡唑-4-基)甲醇
  参考文献：
  名称：

  [EN] ANDROGEN RECEPTOR ANTAGONISTS
  [FR] ANTAGONISTES DU RÉCEPTEUR DES ANDROGÈNES

  摘要：

  描述了抑制雄激素受体的化合物、包含一种或多种这些化合物的药物组合物，以及使用这些化合物治疗癌症的方法。

  公开号：

  WO2019152731A1

文献信息

• [EN] NOVEL COMPOUNDS AS AGONIST FOR PPAR GAMMA AND PPAR ALPHA, METHOD FOR PREPARATION OF THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME<br/>[FR] NOUVEAUX COMPOSES AGONISTES DE PPAR DOLLAR G(G) ET PPAR DOLLAR G(A), LEUR METHODE DE PREPARATION ET COMPOSITION PHARMACEUTIQUE LES CONTENANT
  申请人：LG LIFE SCIENCES LTD

  公开号：WO2005040127A1

  公开（公告）日：2005-05-06

  The present invention relates to novel compounds accelerating the activity of Peroxisome proliferator-activated receptor gamma (PPARϜ) and alpha (PPARα), processes of preparing the same, and pharmaceutical compositions containing the same as an active agent.

  本发明涉及一种新型化合物，可加速过氧化物酶体增殖物激活受体γ（PPARϜ）和α（PPARα）的活性，以及制备这种化合物的方法，以及含有该化合物作为活性成分的药物组合物。
• SUBSTITUTED PYRAZOLE DERIVATIVES
  申请人：ITO Mitsuhiro

  公开号：US20090270359A1

  公开（公告）日：2009-10-29

  The present invention provides a novel pyrazole derivative and an androgen receptor antagonist containing the derivative. The present invention provides a compound represented by the formula (I′) wherein R 1 is a hydrogen atom, a group via a carbon atom, a group via a nitrogen atom, a group via an oxygen atom, or a group via a sulfur atom; R 2 is a phenyl group having cyano (the phenyl group may further have substituent(s) other than cyano); R 3 is a hydrogen atom, a group via a carbon atom, a group via a nitrogen atom, a group via an oxygen atom, or a group via a sulfur atom; R 4 is a cyclic group optionally having substituent(s); and X is methylene optionally having substituent(s), or CO, or a salt thereof.

  本发明提供一种新型吡唑衍生物和含有该衍生物的雄激素受体拮抗剂。本发明提供一种由下式表示的化合物(I′)：其中R1是氢原子、通过碳原子的基团、通过氮原子的基团、通过氧原子的基团或通过硫原子的基团；R2是苯基，带有氰基（苯基可能还有除氰基之外的取代基）；R3是氢原子、通过碳原子的基团、通过氮原子的基团、通过氧原子的基团或通过硫原子的基团；R4是可选地带有取代基的环状基团；X是亚甲基，可选地带有取代基，或CO，或其盐。
• ω-Dialkylaminoalkyl ethers of phenyl-(5-substituted 1-phenyl-1<i>H</i>-pyrazol-4-yl)methanols with analgesic and anti-inflammatory activity
  作者：Giulia Menozzi、Luisa Mosti、Paola Fossa、Francesca Mattioli、Marco Ghia

  DOI：10.1002/jhet.5570340339

  日期：1997.5

  starting from methanols 1a-f via oxidation with pyridinium chlorochromate to aldehydes 2a-f, followed by a Grignard reaction of the latter. Reaction of 3a-f with ω-chloroalkyldialkylamine hydrochlorides afforded a series of aminoether derivatives 4g-t. Compounds 4i,m-p,s showed a good analgesic activity in the acetic acid writhing test in mice. Moreover, compounds 4h,1,s exhibited a moderate anti-inflammatory

  从甲醇1a-f开始，通过用氯铬酸吡啶鎓氧化为醛2a-f，然后进行后者的格利雅反应，制备了一系列甲醇3a-f。3a-f与ω-氯烷基二烷基胺盐酸盐反应，得到一系列氨基醚衍生物4g-t。化合物4i，mp，s在小鼠的乙酸扭体试验中显示出良好的镇痛活性。此外，化合物4h，1，s在角叉菜胶诱导的大鼠水肿试验中显示出中等的抗炎活性。
• 1-6-Substituted (3R,6R)-3-(2,3-Dihydro-1H-Inden-2-Yl)-2,5-Piperazinedione Derivatives as Oxytocin Receptor Antagonists For the Treatment of Preterm Labour, Dysmenorrhea and Endometriosis
  申请人：Leach Colin Andrew

  公开号：US20080242666A1

  公开（公告）日：2008-10-02

  The present invention relates to Compound S of Formula (I).

  本发明涉及化合物S，其化学式为（I）。
• SUBSTITUTED PYRAZOLE DERIVATIVE
  申请人：Ito Mitsuhiro

  公开号：US20100227846A1

  公开（公告）日：2010-09-09

  The present invention provides a novel pyrazole derivative and an androgen receptor antagonist containing the derivative. The present invention provides a compound represented by the formula (I′) wherein R 1 is a hydrogen atom, a group via a carbon atom, a group via a nitrogen atom, a group via an oxygen atom, or a group via a sulfur atom; R 2 is a phenyl group having cyano (the phenyl group may further have substituent(s) other than cyano); R 3 is a hydrogen atom, a group via a carbon atom, a group via a nitrogen atom, a group via an oxygen atom, or a group via a sulfur atom; R 4 is a cyclic group optionally having substituent(s); and X is methylene optionally having substituent(s), or CO, or a salt thereof.

  本发明提供了一种新的吡唑衍生物和含有该衍生物的雄激素受体拮抗剂。本发明提供了一种由式(I')表示的化合物，其中R1是氢原子，通过碳原子的基团，通过氮原子的基团，通过氧原子的基团或通过硫原子的基团; R2是具有氰基的苯基（苯基可以进一步具有除氰基以外的取代基）; R3是氢原子，通过碳原子的基团，通过氮原子的基团，通过氧原子的基团或通过硫原子的基团; R4是可选地具有取代基的环状基团; X是可选地具有取代基的亚甲基，或CO，或其盐。